A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? / Herbert Tilg, Maria Effenberger, Timon E. Adolph
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Expert opinion on investigational drugs - 29(2020), 2, Seite 103-106 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tilg, Herbert [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Canakinumab |
|---|
| Umfang: |
1 Online-Ressource (4 p) |
|---|
| doi: |
10.1080/13543784.2020.1681397 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011200340 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011200340 | ||
| 003 | DE-627 | ||
| 005 | 20230720210239.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13543784.2020.1681397 |2 doi | |
| 035 | |a (DE-627)KFL011200340 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/13543784.2020.1681397 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Tilg, Herbert |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)? |c Herbert Tilg, Maria Effenberger, Timon E. Adolph |
| 264 | 1 | |c 2020 | |
| 300 | |a 1 Online-Ressource (4 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 653 | |a Canakinumab | ||
| 653 | |a diabetes | ||
| 653 | |a drug therapy | ||
| 653 | |a metabolic inflammation | ||
| 653 | |a nonalcoholic fatty liver disease | ||
| 700 | 1 | |a Effenberger, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Adolph, Timon E. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on investigational drugs |d Abingdon, Oxon : Routledge, Taylor & Francis, 1994 |g 29(2020), 2, Seite 103-106 |h Online-Ressource |w (DE-627)KFL000006041 |w (DE-600)2030114-5 |w (DE-576)302969314 |x 1744-7658 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2020 |g number:2 |g pages:103-106 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/13543784.2020.1681397 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2020 |e 2 |h 103-106 | ||